Every transformative medicine begins with an ambitious idea, but only a handful ever become therapies that physicians can confidently prescribe. Between scientific discovery and patient care lies an extensive journey of analytical testing, regulatory scrutiny and uncompromising quality assurance. It is a journey where precision matters as much as innovation, and where every result can determine whether a promising therapy moves forward or returns to the laboratory. For pharmaceutical and biotechnology companies around the world, Solvias has become one of the trusted partners helping move ahead in that critical path.

Headquartered in Basel, Switzerland—one of the world’s leading pharmaceutical hubs—Solvias was established over twenty-five years ago as a spin-off from Novartis. What began as an organization specializing in quality control testing for small-molecule pharmaceuticals has steadily evolved into a global scientific partner supporting virtually every major therapeutic modality, therapies, RNA-based medicines and other advanced biologics. The company’s growth mirrors the remarkable transformation occurring across the pharmaceutical industry itself. Medicines that were once relatively straightforward chemical compounds have become highly sophisticated biological products designed to target diseases with unprecedented precision. These advances are opening new possibilities for patients while simultaneously creating entirely new analytical and regulatory challenges. “Our role is to make sure medicines are safe and effective before they move into clinical trials or for commercial release,” says Daniel Galbraith, Chief Scientist Officer at Solvias. “As medicines become more complex, understanding exactly how to characterize and analyse them becomes increasingly important.”

Building Confidence Before Every Clinical Milestone

Although Solvias is widely recognized as a leading contract research organization (CRO), its role extends well beyond laboratory testing. The company operates at the heart of the Chemistry, Manufacturing and Controls (CMC) process, providing the analytical evidence that demonstrates a medicine consistently meets quality standards before regulators permit it to advance.

Every therapeutic entering clinical development or commercial manufacturing must satisfy rigorous requirements established by regulatory authorities. Solvias works alongside pharmaceutical innovators to determine exactly which analytical tests are required, develop scientifically sound testing strategies, execute those studies and compile the comprehensive data packages that become part of regulatory submissions. Its scientists first seek to understand the product itself. Is it a vaccine? A gene therapy? A cell therapy? A monoclonal antibody? Each therapeutic class requires a different analytical approach and must satisfy different regulatory expectations.

The destination is equally important. Companies rarely develop medicines for a single market. Many aspire to commercialize therapies globally, but regulatory agencies—including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and authorities throughout Asia—often require different analytical evidence before granting approval. Helping customers with those varying requirements has become one of Solvias’ greatest strengths. Rather than simply conducting requested tests, the company helps clients build regulatory strategies that support successful submissions across multiple markets.

More Than Testing—A Scientific Partnership

Naturally, customers want to reach clinical trials and commercialization as quickly as possible. Solvias understands that urgency. At the same time, scientific rigor cannot be compromised. “Drug developers want to move as quickly as possible because patients are waiting,” Galbraith explains. “But speed has to be balanced with generating the right quality data. Without the confidence of regulators, no therapy moves forward.”

Finding that balance defines the company’s philosophy. Working with hundreds of pharmaceutical and biotechnology companies gives Solvias a perspective few organizations possess. Its scientists see analytical strategies across a broad spectrum of therapeutic programs, enabling them to recognize proven approaches while helping customers avoid unnecessary complexity. Galbraith often describes this as finding the “Goldilocks” balance—not too much testing, not too little, but exactly the amount regulators expect.

Performing excessive studies increases costs and delays development. Insufficient testing creates regulatory questions that can slow programs even further. Solvias helps clients navigate between those extremes, designing analytical programs that are scientifically robust while remaining commercially practical.

Moreover, Galbraith believes Solvias distinguishes itself not by generating routine analytical results, but by helping customers navigate the unexpected. Analytical testing does not always produce straightforward answers. Occasionally, a batch fails a critical quality test or generates unexpected data. For pharmaceutical manufacturers, especially when individual production batches may represent millions of dollars in value, the next step becomes critically important. Rather than simply reporting a pass-or-fail result, Solvias works closely with customers to determine why an issue occurred, evaluate additional analytical evidence and identify the most scientifically appropriate regulatory path forward. “Customers aren’t simply paying for a laboratory result,” Galbraith says. “They’re paying for the scientific conversation and partnership that follows.” This collaborative philosophy frequently prevents unnecessary delays, helps preserve valuable manufacturing batches where scientifically justified and provides customers with the confidence needed to engage regulators using sound analytical evidence.

Planning for Success Before the Samples Arrive

Scientific excellence alone is not enough to accelerate drug development. Capacity planning has become equally important. Specialized laboratories cannot simply expand overnight. Sophisticated analytical instruments, highly trained scientists and carefully managed workflows require thoughtful scheduling to maintain quality while meeting demanding timelines. For that reason, Solvias encourages customers to engage early in development rather than waiting until manufacturing has already begun. Early collaboration allows laboratory resources to be aligned with manufacturing schedules, reducing delays while ensuring testing begins as soon as materials become available.

Solvias has one of the highest ratios of scientists with higher degrees and hands on biopharma experience in their operational teams. Galbraith: “Because we have over 175 PhDs working at the company, we can apply sophisticated science-based solutions to the challenges our customers bring. At the same time our teams are always learning from our customers and the regulators with new ideas for products and the challenging scrutiny the regulators bring to submissions. The combination of such scientific expertise and industry experience provides a rare resource in our field.”

Keeping Pace with Increasing Scientific Complexity

The rapid evolution of modern therapeutics has fundamentally changed analytical science. Many emerging medicines combine multiple biological components into highly sophisticated products whose structures are significantly more difficult to characterize than traditional pharmaceuticals. Understanding how these molecules behave, how they degrade and how manufacturing influences their quality requires analytical capabilities that scarcely existed a decade ago.

Fortunately, analytical technology has advanced just as rapidly. Instead of relying on multiple independent analytical methods, today’s instruments often provide comprehensive molecular characterization using a single workflow, maintaining the advantages of orthogonal analytical measurements with a single instrument. Technologies such as advanced mass spectrometry have transformed laboratory operations, allowing scientists to analyse increasingly complex biological molecules with greater speed, higher sensitivity and substantially improved accuracy. For Solvias, these advances are not simply about adopting new equipment—they are about giving pharmaceutical innovators greater confidence while reducing turnaround times, conserving valuable samples and generating richer scientific insight than ever before.

Next Generation Sequencing Opens New Possibilities

Among the technologies reshaping analytical science, Next Generation Sequencing (NGS) stands out as one of the most transformative. Originally developed as a research tool, NGS has rapidly become an important component of Good Manufacturing Practice (GMP)-compliant analytical testing. Solvias has been at the forefront of applying this technology to pharmaceutical quality control. Instead of relying solely on traditional microbiological methods that may require days or even weeks to identify contamination, NGS enables scientists to rapidly sequence DNA or RNA and determine whether bacterial or viral contaminants are present within a sample. Equally important, the technology can confirm the identity of biological products such as vaccines by verifying their genetic signatures. The implications extend far beyond contamination testing. Solvias is applying NGS to understand how therapies interact with different cell types, providing early insights into drug behaviour before treatments ever reach clinical trials. By analysing genetic activity within heart, liver, kidney or muscle cells, scientists can better understand both therapeutic effects and potential safety concerns long before human studies begin. These capabilities are helping build more predictive laboratory models that could eventually reduce the size, duration and cost of clinical trials while improving confidence in new therapies.

Helping Shape the Future of Pharmaceutical Quality

Looking ahead, Solvias sees its mission extending beyond analytical excellence. Healthcare systems worldwide are placing increasing emphasis on the affordability of medicines. Governments, healthcare providers and patients all expect innovative therapies to become not only safer and more effective but also more accessible. Solvias recognizes that analytical science plays an important role in achieving that objective. By simplifying testing strategies, adopting smarter technologies, improving laboratory efficiency, and eliminating unnecessary complexity, the company helps reduce the challenges during drug development. That contribution ultimately supports pharmaceutical innovators in bringing life-changing therapies to market more efficiently while preserving the rigorous quality standards patients deserve.